STOCK TITAN

Amgen (AMGN) 10-K Filings

AMGN NASDAQ

Here are the 10-K annual reports from Amgen Inc (AMGN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.

Rhea-AI Summary

Amgen Inc. reports a large, diversified biotechnology business focused on human therapeutics, with 2025 product sales of $35,148 million, up from $32,026 million in 2024 and $26,910 million in 2023. U.S. sales were $25,656 million and rest-of-world sales were $9,492 million in 2025.

The company’s portfolio spans osteoporosis (Prolia, EVENITY), cardiovascular disease (Repatha), inflammation and immunology (ENBREL, Otezla, TEZSPIRE), oncology and hematology (BLINCYTO, KYPROLIS, Vectibix, IMDELLTRA/IMDYLLTRA), rare diseases (TEPEZZA, KRYSTEXXA, TAVNEOS, UPLIZNA) and multiple biosimilars. Key 2025–2026 regulatory events include broader U.S. Repatha labeling, multiple new UPLIZNA indications, full approval of IMDELLTRA in extensive-stage small cell lung cancer, new TEZSPIRE indications, and EU approval of TEPEZZA.

Amgen highlights an extensive pipeline, led by obesity and cardiometabolic candidate MariTide in multiple Phase 3 programs and positive long-term Phase 2 data, as well as cardiovascular RNA agent olpasiran and several biosimilar antibodies in late-stage development. The company also faces rising biosimilar and generic competition, loss of key patents such as RANKL antibodies for Prolia/XGEVA, and U.S. pricing pressure from the Inflation Reduction Act, including mandated Medicare price cuts for ENBREL from 2026 and Otezla from 2027.